---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-123807"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T17:14:42.707463+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics amends credit agreement, terminates RIFA, lowers warrant exercise price to $3.6452

## Summary
- Entered Second Amendment to Credit Agreement with Oaktree; converts $30M RIFA financing into Tranche A-2 Term Loan.
- Increased OnkosXcel investment cap to $30.865M; pays 0.25% exit fee on loans repaid.
- Reduces exercise price of existing warrants from $20.04 to $3.6452; issues new warrants for 69,630 shares at same price.
- Terminates Revenue Interest Financing Agreement (RIFA); all future funding commitments cancelled.

## SEC filing metadata
- accession: 0001104659-23-123807
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/tm2332261d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-123807
- JSON: https://secwatch.observer/filing/0001104659-23-123807.json
- Plain text: https://secwatch.observer/filing/0001104659-23-123807.txt

## Key facts
- Debt Financings
  BioXcel Therapeutics, Inc. amended term loan of The $30,000,000 in financing previously provided to the Company under the RIFA was converted to an outstanding loan unde with Lenders.
  - Instrument: term loan
  - Principal: The $30,000,000 in financing previously provided to the Company under the RIFA was converted to an outstanding loan unde
  - Counterparty: Lenders
  - Event: amendment
  source text: Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865,000 at any time outstanding in OnkosXcel Therapeutics, LLC (“OnkosXcel”), increased from $30,000,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm
- Material Agreements
  BioXcel Therapeutics, Inc. terminated Revenue Interest Financing Agreement with the purchasers party thereto and Oaktree Fund Administration LLC (effective 2023-12-05).
  - Action: termination
  - Counterparty: the purchasers party thereto and Oaktree Fund Administration LLC
  - Effective: 2023-12-05
  source text: the Company terminated the Revenue Interest Financing Agreement (as amended from time to time, the “RIFA”) by and among the Company, the purchasers party thereto (the “Purchasers”) and OFA, as administrative agent
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm
- Material Agreements
  BioXcel Therapeutics, Inc. amended Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement with Oaktree Fund Administration LLC and lenders valued at up to a maximum of $30,865,000 at any time outstanding (effective 2023-12-05).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Oaktree Fund Administration LLC and lenders
  - Value: up to a maximum of $30,865,000 at any time outstanding
  - Effective: 2023-12-05
  source text: BioXcel Therapeutics, Inc. (the “Company”) entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the “Second Amendment”), which amended the Credit Agreement and Guaranty
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.